Your browser is no longer supported. Please, upgrade your browser.
ProQR Therapeutics N.V.
Index- P/E- EPS (ttm)-1.12 Insider Own2.37% Shs Outstand50.19M Perf Week0.16%
Market Cap376.60M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float48.63M Perf Month-4.45%
Income-56.20M PEG- EPS next Q-0.29 Inst Own54.00% Short Float4.23% Perf Quarter24.60%
Sales11.40M P/S33.04 EPS this Y32.40% Inst Trans2.69% Short Ratio0.59 Perf Half Y46.59%
Book/sh1.37 P/B4.55 EPS next Y-13.90% ROA-45.90% Target Price- Perf Year17.33%
Cash/sh1.51 P/C4.12 EPS next 5Y- ROE-64.70% 52W Range3.40 - 9.46 Perf YTD48.33%
Dividend- P/FCF- EPS past 5Y-0.80% ROI-46.50% 52W High-33.19% Beta0.52
Dividend %- Quick Ratio7.80 Sales past 5Y23.90% Gross Margin- 52W Low85.88% ATR0.43
Employees150 Current Ratio7.80 Sales Q/Q-25.00% Oper. Margin- RSI (14)52.69 Volatility7.94% 6.51%
OptionableYes Debt/Eq0.60 EPS Q/Q32.60% Profit Margin- Rel Volume0.20 Prev Close6.23
ShortableYes LT Debt/Eq0.56 Earnings- Payout- Avg Volume3.49M Price6.32
Recom1.60 SMA202.66% SMA506.47% SMA20026.35% Volume526,779 Change1.44%
May-03-21Initiated Stifel Buy $20
Mar-25-21Reiterated Citigroup Buy $33 → $44
Nov-03-20Resumed Cantor Fitzgerald Overweight $22
Mar-12-19Reiterated Chardan Capital Markets Buy $21 → $25
Dec-19-18Initiated RBC Capital Mkts Outperform
Nov-15-18Initiated Citigroup Buy $32
Sep-19-18Initiated Evercore ISI Outperform
Sep-26-17Reiterated JMP Securities Mkt Outperform $14 → $20
Jun-20-16Initiated Chardan Capital Markets Neutral $4.50
Oct-15-14Initiated Deutsche Bank Buy $32
Oct-13-14Initiated H.C. Wainwright Buy $40
May-06-21 09:05AM  
May-04-21 09:35AM  
Apr-23-21 07:00AM  
Apr-22-21 07:00AM  
Apr-20-21 07:00AM  
Apr-13-21 04:15PM  
Apr-07-21 10:58AM  
Apr-05-21 04:15PM  
Apr-02-21 04:15PM  
Mar-30-21 10:25PM  
Mar-26-21 12:33PM  
Mar-24-21 01:30PM  
Mar-19-21 06:12AM  
Mar-17-21 07:00AM  
Mar-02-21 04:30PM  
Feb-25-21 07:00AM  
Feb-16-21 04:30PM  
Jan-21-21 10:34AM  
Jan-18-21 06:37AM  
Jan-07-21 07:00AM  
Dec-18-20 07:00AM  
Nov-30-20 09:32PM  
Nov-18-20 07:00AM  
Nov-17-20 08:21AM  
Nov-16-20 08:35AM  
Nov-02-20 07:00AM  
Oct-05-20 07:00AM  
Sep-24-20 04:10PM  
Sep-21-20 03:23PM  
Sep-03-20 07:00AM  
Aug-06-20 04:30PM  
Jul-23-20 09:21AM  
Jul-21-20 07:00AM  
Jul-14-20 04:30PM  
Jul-13-20 04:30PM  
Jun-29-20 08:32AM  
Jun-23-20 11:32AM  
Jun-22-20 02:42PM  
Jun-15-20 10:00AM  
Jun-12-20 07:00AM  
Jun-08-20 07:00AM  
May-29-20 08:55AM  
May-25-20 07:00AM  
May-07-20 08:55AM  
Apr-28-20 08:47AM  
Mar-31-20 06:00AM  
Mar-25-20 04:15PM  
Mar-05-20 08:29AM  
Feb-28-20 11:23AM  
Feb-26-20 07:00AM  
Feb-24-20 07:00AM  
Feb-06-20 07:00AM  
Jan-30-20 07:00AM  
Jan-21-20 04:09AM  
Jan-06-20 09:45AM  
Dec-23-19 11:51AM  
Dec-17-19 05:20PM  
Dec-12-19 03:19PM  
Dec-11-19 02:42PM  
Nov-21-19 08:25AM  
Nov-18-19 07:23AM  
Nov-13-19 07:00AM  
Nov-06-19 06:09PM  
Nov-05-19 11:45AM  
Oct-24-19 12:50PM  
Oct-23-19 07:42AM  
Oct-18-19 08:20AM  
Oct-16-19 07:06AM  
Oct-15-19 11:17PM  
Oct-10-19 07:31AM  
Oct-07-19 07:00AM  
Oct-01-19 09:09AM  
Sep-30-19 07:00AM  
Sep-24-19 10:33AM  
Sep-13-19 11:08AM  
Sep-09-19 07:00AM  
Aug-14-19 12:18PM  
Aug-13-19 11:53AM  
Aug-12-19 07:00AM  
Aug-07-19 10:05AM  
Jul-29-19 07:00AM  
Jul-26-19 01:31PM  
Jul-02-19 07:00AM  
Jun-29-19 05:34PM  
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.